High-Quality Retatrutide CAS NO: 2381089-83-2 for Obesity and T2DM - Leading China Suppliers and Factory Solutions Quotes, Pricelist

,

Obesity and type 2 diabetes mellitus (T2DM) pose serious health challenges worldwide, leading to increased morbidity and mortality rates. Retatrutide, an innovative triple receptor agonist that targets glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, offers a transformative solution in the treatment of obesity and T2DM. As a leading product from trusted suppliers in China, our factory is dedicated to advancing pharmacotherapy that addresses these global health issues effectively.

,

Product Description

Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy.

Mechanism & Efficacy

Retatrutide is a novel multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed to enhance glucose regulation, promote weight loss, and support metabolic health. It is under active investigation in clinical and preclinical research for obesity and type 2 diabetes management.

Dosage & Research Use

Retatrutide is currently an investigational peptide in Phase 3 clinical trials and not yet FDA‑approved for clinical use. Trial protocols have explored once‑weekly subcutaneous doses ranging from 1 mg up to 12 mg, often titrated over multiple 4‑week intervals to balance efficacy and tolerability.

Frequently Asked Questions

What is Retatrutide and how does it work?
Retatrutide is a novel triple receptor agonist peptide that targets GLP-1, GIP, and glucagon receptors. It is designed to enhance glucose regulation, support metabolic health, and promote weight loss.
What medical conditions is Retatrutide being researched for?
Retatrutide is currently under active investigation in clinical and preclinical research for the management of obesity and type 2 diabetes mellitus (T2DM).
Is Retatrutide approved by the FDA?
No, Retatrutide is currently an investigational peptide in Phase 3 clinical trials and is not yet approved by the FDA for clinical use.
What dosages of Retatrutide are being studied in clinical trials?
Trial protocols have explored once-weekly subcutaneous doses of Retatrutide ranging from 1 mg up to 12 mg.
Why is titration used in Retatrutide dosing protocols?
Doses are often titrated over multiple 4-week intervals during trials to carefully balance the treatment's efficacy with patient tolerability.

Related Products